BR0317520A - Composições de inibidores de proteìna de transferência de ésteres de colesterilo e inibidores de hmg-coa redutase - Google Patents

Composições de inibidores de proteìna de transferência de ésteres de colesterilo e inibidores de hmg-coa redutase

Info

Publication number
BR0317520A
BR0317520A BR0317520-0A BR0317520A BR0317520A BR 0317520 A BR0317520 A BR 0317520A BR 0317520 A BR0317520 A BR 0317520A BR 0317520 A BR0317520 A BR 0317520A
Authority
BR
Brazil
Prior art keywords
inhibitors
hmg
transfer protein
compositions
coa reductase
Prior art date
Application number
BR0317520-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Walter Christian Babcock
Dwayne Thomas Friesen
Daniel Tod Smithey
Ravi Mysore Shanker
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BR0317520A publication Critical patent/BR0317520A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
BR0317520-0A 2002-12-20 2003-12-18 Composições de inibidores de proteìna de transferência de ésteres de colesterilo e inibidores de hmg-coa redutase BR0317520A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43532802P 2002-12-20 2002-12-20
PCT/IB2003/006170 WO2004056395A1 (en) 2002-12-20 2003-12-18 Compositions of cholesteryl ester transfer protein inhibitors and hmg-coa reductase inhibitors

Publications (1)

Publication Number Publication Date
BR0317520A true BR0317520A (pt) 2005-11-16

Family

ID=32682218

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0317520-0A BR0317520A (pt) 2002-12-20 2003-12-18 Composições de inibidores de proteìna de transferência de ésteres de colesterilo e inibidores de hmg-coa redutase

Country Status (8)

Country Link
US (1) US20040132771A1 (https=)
EP (1) EP1578448A1 (https=)
JP (1) JP2006512361A (https=)
AU (2) AU2003285703A1 (https=)
BR (1) BR0317520A (https=)
CA (1) CA2510458A1 (https=)
MX (1) MXPA05006167A (https=)
WO (2) WO2004056395A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003000295A2 (en) * 2001-06-21 2003-01-03 Pfizer Products Inc. Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors
KR20050088190A (ko) * 2002-12-20 2005-09-02 화이자 프로덕츠 인코포레이티드 콜레스테릴 에스터 전달 단백질 억제제 및 ｈｍｇ-ｃｏａ환원 효소 억제제를 포함하는 투약 형태
KR20110117731A (ko) 2003-05-30 2011-10-27 랜박시 래보러터리스 리미티드 치환된 피롤 유도체와 ｈｍｇ―ｃｏ 억제제로서의 이의 용도
US20090088465A1 (en) * 2004-12-02 2009-04-02 Stephen Craig Dyar Pharmaceutical Compositions of Amorphous Atorvastatin and Process for Preparing Same
CA2601762A1 (en) * 2005-02-03 2006-08-10 Pfizer Products Inc. Dosage forms providing controlled and immediate release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors
WO2006085217A2 (en) * 2005-02-08 2006-08-17 Pfizer Products Inc. Solid adsorbates of hydrophobic drugs
US8828438B2 (en) 2005-05-31 2014-09-09 Bend Research, Inc. Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors and HMG-CoA reductase
CA2627599A1 (en) * 2005-11-08 2007-05-18 Ranbaxy Laboratories Limited Process for (3r,5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino)carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt
WO2008020314A2 (en) * 2006-03-14 2008-02-21 Ranbaxy Laboratories Limited Statin stabilizing dosage formulations
WO2007134158A2 (en) * 2006-05-12 2007-11-22 Drugtech Corporation Granules comprising calcium carbonate, a binder and a porosity increasing agent, processes of manufacturing, use in therapy
US8099298B2 (en) * 2007-02-14 2012-01-17 Genelex, Inc Genetic data analysis and database tools
CN102089016A (zh) * 2008-02-27 2011-06-08 托门医学股份公司 植入物及其制备方法
CA2718255C (en) 2008-03-11 2016-08-23 Aska Pharmaceutical Co., Ltd. Solid dispersion and pharmaceutical composition of the same, and production processes thereof
DK2306982T3 (en) * 2008-06-27 2015-04-20 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical compositions of rosuvastatin calcium
JPWO2010092925A1 (ja) * 2009-02-12 2012-08-16 あすか製薬株式会社 固体分散体とその医薬組成物、並びにそれらの製造方法
US9107983B2 (en) 2010-10-27 2015-08-18 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising statins
US8877221B2 (en) 2010-10-27 2014-11-04 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same
US9308190B2 (en) 2011-06-06 2016-04-12 Warsaw Orthopedic, Inc. Methods and compositions to enhance bone growth comprising a statin
EP2951741A2 (en) 2013-02-03 2015-12-09 Genelex Corporation Systems and methods for quantification and presentation of medical risk arising from unknown factors
US20200147032A1 (en) 2018-11-14 2020-05-14 Robert K. Prud'homme Dihydromyricetin hot melt extrusion formulations and methods for forming them

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US35125A (en) * 1862-04-29 Improvement in spring-balances
JPS5612114B2 (https=) * 1974-06-07 1981-03-18
US4231938A (en) * 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4294926A (en) * 1979-06-15 1981-10-13 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4319039A (en) * 1979-06-15 1982-03-09 Merck & Co., Inc. Preparation of ammonium salt of hypocholesteremic fermentation product
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
MX7065E (es) * 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
US4450171A (en) * 1980-08-05 1984-05-22 Merck & Co., Inc. Antihypercholesterolemic compounds
JPS5889191A (ja) * 1981-11-20 1983-05-27 Sankyo Co Ltd ３−ヒドロキシ−ｍｌ−２３６ｂ誘導体の製造法
FR2525108B1 (fr) * 1982-04-19 1989-05-12 Elan Corp Ltd Medicaments a haut degre de solubilite et procede pour leur obtention
US4739073A (en) * 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
US5354772A (en) * 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US4911165A (en) * 1983-01-12 1990-03-27 Ethicon, Inc. Pliabilized polypropylene surgical filaments
US4686237A (en) * 1984-07-24 1987-08-11 Sandoz Pharmaceuticals Corp. Erythro-(E)-7-[3'-C1-3 alkyl-1'-(3",5"-dimethylphenyl)naphth-2'-yl]-3,5-dihydroxyhept-6-enoic acids and derivatives thereof
US4647576A (en) * 1984-09-24 1987-03-03 Warner-Lambert Company Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis
US5225192A (en) * 1988-10-17 1993-07-06 Vectorpharma International S.P.A. Poorly soluble medicaments supported on polymer substances in a form suitable for increasing their dissolving rate
US5569469A (en) * 1984-10-16 1996-10-29 Vectorpharma International, S.P.A. Poorly soluble medicaments supported on polymer substances in a form suitable for increasing their dissolving rate
IE63321B1 (en) * 1986-02-03 1995-04-05 Elan Corp Plc Drug delivery system
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US5110940A (en) * 1987-02-25 1992-05-05 Bristol-Myers Company Antihypercholesterolemic tetrazole compounds
US4820850A (en) * 1987-07-10 1989-04-11 Merck & Co., Inc. Process for α-C-alkylation of the 8-acyl group on mevinolin and analogs thereof
US5030447A (en) * 1988-03-31 1991-07-09 E. R. Squibb & Sons, Inc. Pharmaceutical compositions having good stability
US5180589A (en) * 1988-03-31 1993-01-19 E. R. Squibb & Sons, Inc. Pravastatin pharmaceuatical compositions having good stability
IT1216570B (it) * 1988-04-08 1990-03-08 Vectorpharma Int Composizione farmaceutiche a rilascio controllato e procedimento per la loro preparazione.
US5049696A (en) * 1988-04-11 1991-09-17 Merck & Co., Inc. Antihypercholesterolemic compounds
US4916239A (en) * 1988-07-19 1990-04-10 Merck & Co., Inc. Process for the lactonization of mevinic acids and analogs thereof
US4866058A (en) * 1988-07-27 1989-09-12 Izydore Robert A Method for control of hyperlipidemia
IT1226726B (it) * 1988-07-29 1991-02-05 Zambon Spa Composti attivi come inibitori della biosintesi del colesterolo.
US5196440A (en) * 1988-07-29 1993-03-23 Zambon Group S.P.A. Compounds active as inhibitors of the cholesterol biosynthesis
US5011947A (en) * 1988-08-25 1991-04-30 Bristol-Myers Antihypercholesterolemic alkylene compounds
US5290946A (en) * 1988-10-13 1994-03-01 Sandoz Ltd. Processes for the synthesis of 3-(substituted indolyl-2-yl)propenaldehydes
US5118853A (en) * 1988-10-13 1992-06-02 Sandoz Ltd. Processes for the synthesis of 3-disubstituted aminoacroleins
IT1227626B (it) * 1988-11-28 1991-04-23 Vectorpharma Int Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione
US5166364A (en) * 1989-02-27 1992-11-24 E. R. Squibb & Sons, Inc. Mevinic acid derivatives useful as antihypercholesterolemic agents and method for preparing same
US5099035A (en) * 1989-02-27 1992-03-24 E. R. Squibb & Sons, Inc. Mevinic acid derivatives useful as antihypercholesterolemic agents and method for preparing same
US5189164A (en) * 1989-05-22 1993-02-23 Sandoz Ltd. Processes for the synthesis of syn-(E)-3,5-dihydroxy-7-substituted hept-6-enoic and heptanoic acids and derivatives and intermediates thereof
US5010105A (en) * 1989-06-09 1991-04-23 Merck & Co., Inc. Antihypercholesterolemic compounds
US4949437A (en) * 1989-07-11 1990-08-21 Anderson Travis B Shoelace knot retaining apparatus
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US4970221A (en) * 1989-07-28 1990-11-13 E. R. Squibb & Sons, Inc. 3,5-dihydroxypentanoic acid derivatives useful as antihypercholesterolemic agents and method for preparing same
US5106992A (en) * 1989-07-28 1992-04-21 E. R. Squibb & Sons, Inc. 3,5-dihydroxypentanoic acid derivatives useful as antihypercholesterolemic agents and method for preparing same
US5025017A (en) * 1989-09-28 1991-06-18 E. R. Squibb & Sons, Inc. Seco-mevinic acid derivatives useful as antihypercholesterolemic agents and new intermediates
US5189180A (en) * 1989-09-28 1993-02-23 E. R. Squibb & Sons, Inc. Seco-mevinic acid derivatives useful as antihypercholesterolemic agents and new intermediates
US5217992A (en) * 1989-10-04 1993-06-08 Bristol-Myers Squibb Company Tocotrienols in the treatment of hypercholesterolemia, hyperlipidemia and thromboembolic disorders
IT1237793B (it) * 1989-12-21 1993-06-17 Zambon Spa Composti attivi come inibitori dell'enzima hmg-coa reduttasi
US5049577A (en) * 1990-01-29 1991-09-17 E. R. Squibb & Sons, Inc. 2-pyrrolidone substituted dihydroxy alkanoic, alkenoic and alkynoic acids, compositions and HMG-CoA reductase inhibition therewith
IT1241417B (it) * 1990-03-06 1994-01-14 Vectorpharma Int Composizioni terapeutiche a rilascio controllato di farmaci supportatisu polimeri reticolati e rivestiti con film polimerici,e loro processodi preparazione
US5177080A (en) * 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
HU9203780D0 (en) * 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
US5157134A (en) * 1992-03-12 1992-10-20 E. R. Squibb & Sons, Inc. Dihydroxyheptanoic acids containing an oxabicycloheptane nucleus useful as antihypercholesterolemic agents
US5298627A (en) * 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5773021A (en) * 1994-03-14 1998-06-30 Vetoquinol S.A. Bioadhesive ophthalmic insert
TW487582B (en) * 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
DE19627431A1 (de) * 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine
HRP970330B1 (en) * 1996-07-08 2004-06-30 Bayer Ag Cycloalkano pyridines
US6207671B1 (en) * 1996-07-08 2001-03-27 Bayer Aktiengesellschaft Cycloalkano-pyridines
JPH11131049A (ja) * 1997-10-28 1999-05-18 Japan Science & Technology Corp シリカ有機物複合体とその製造方法
US6147089A (en) * 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
GT199900147A (es) * 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6147090A (en) * 1998-09-17 2000-11-14 Pfizer Inc. 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6140342A (en) * 1998-09-17 2000-10-31 Pfizer Inc. Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
AU2157400A (en) * 1998-12-23 2000-07-31 G.D. Searle & Co. Combinations of cholesteryl ester transfer protein inhibitors and hmg coa reductase inhibitors for cardiovascular indications
ES2306646T3 (es) * 1999-02-09 2008-11-16 Pfizer Products Inc. Composiciones de farmacos basicos con biodisponibilidad incrementada.
CO5271716A1 (es) * 1999-11-30 2003-04-30 Pfizer Prod Inc Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida
HN2000000203A (es) * 1999-11-30 2001-06-13 Pfizer Prod Inc Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas.
US7115279B2 (en) * 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
AP2003002743A0 (en) * 2000-08-15 2003-03-31 Pfizer Prod Inc Therapeutic combination of a cept inhibitor and atorvastatin
EE200400034A (et) * 2001-06-22 2004-06-15 Pfizer Products Inc. Amorfse ravimaine adsorbaatide farmatseutilised kompositsioonid
JP2005509001A (ja) * 2001-10-29 2005-04-07 セリクス， インコーポレイテッド 投薬形態の三次元懸濁液プリンティング
WO2004002443A1 (en) * 2002-06-26 2004-01-08 Tuo Jin Solid dosage forms for rapid dissolution of poorly soluble drugs
US20040053842A1 (en) * 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents

Also Published As

Publication number Publication date
WO2004056395A1 (en) 2004-07-08
WO2004056396A1 (en) 2004-07-08
JP2006512361A (ja) 2006-04-13
US20040132771A1 (en) 2004-07-08
EP1578448A1 (en) 2005-09-28
MXPA05006167A (es) 2005-08-26
AU2003285703A1 (en) 2004-07-14
AU2003285677A1 (en) 2004-07-14
CA2510458A1 (en) 2004-07-08

Similar Documents

Publication Publication Date Title
BR0317520A (pt) Composições de inibidores de proteìna de transferência de ésteres de colesterilo e inibidores de hmg-coa redutase
GC0000221A (en) Pyrimidinone compounds, processes for their preparation, intermediates useful in their preparation, and pharmaceutical compositions containing them
TW200517145A (en) Dosage forms of cholesteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
BR0308613A (pt) Combinação de compostos orgânicos
AU2482800A (en) Sulphohydroxamic acids and sulphohydroxamates and their use as mek inhibitors
DK1569899T3 (da) Substituerede 3-alkyl- og 3-arylalkyl-1H-indol-1-yl-eddikesyrederivater som inhibitorer af plasminogenaktivator-inhibitor-1 (PAI-1)
DE69942342D1 (de) Tocopherole, tocotrienole, sonstige chroman- und seitenkettenderivate, sowie deren verwendungen
DE69912581D1 (de) Biarylessigsäure-derivate und ihre verwendung als cox-2 inhibitoren
EE04990B1 (et) HMG reduktaasi inhibiitorit sisaldavad farmatseutilised kompositsioonid, nende kasutamine ja saamismeetod
BR0307277A (pt) Composições farmacêuticas de inibidores da proteìna de transferencia do éster de colesterilo
BR0317593A (pt) Formas de dosagem compreendendo um inibidor de cetp e um inibidor de hmg-coa reductase
DE60113080D1 (de) 4-amino-5-cyano-2-anilino-pyrimidin-derivate zur verwendung als inhibitoren von zellzyklus-kinasen
ATE461700T1 (de) Dosierungsform enthaltend einen cetp-hemmer und einen hmg-coa reduktase hemmer
EA200200510A1 (ru) 4-карбоксиамино-2-этил-1,2,3,4-тетрагидрохинолин в кристаллической форме как ингибитор сетр
BR0307060A (pt) ésteres hidroxamato do ácido n-(fenil 4-substituìdo)-antranìlico
AU2003304226A1 (en) Inhibition of rosin crystallization
AU2003287249A1 (en) Organic acid containing compositions and methods for use thereof
AU6055594A (en) Substituted pyrroles
BRPI0417138A (pt) n-alquil-pirroles como inibidores de hmg-coa-redutase
AU2003303074A1 (en) Sphingolipid derivatives modified by polyethylene glycol and composition containing the same
AU2003206148A1 (en) Nivalenol as specific inhibitor to transcriptional factor c-maf and pharmaceutical compositions comprising the same
AU2003208294A1 (en) Improvement of flue gas desulfurization gypsum-dewatering through crystal habit modification by carboxylic acids
ATE508112T1 (de) 3-substituierte 5- und 6-aminoalkylindol-2- carbonsäureamide und verwandte analoga als inhibitoren von caseinkinase i
AUPS179302A0 (en) Use of topical compositions for the control of microbial diseases of the nail
ATE461174T1 (de) Neue piperidinderivate und deren verwendung als monoaminneurotransmitter-wiederaufnahmehemmer

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A, 7A E 8A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2144 DE 07/02/2012.